Peter DiLaura is an accomplished biotechnology executive with over 20 years of experience in the life sciences industry. Driven by a passion for the role of emerging technologies in drug discovery, Peter’s career has spanned therapeutic platforms, genomics technologies, systems biology tools, and data sciences. He is an advisor to a number of pharmaceutical and biotechnology companies and venture capital firms.
From 2010 to 2016, Peter was the CEO of Second Genome, a South San Francisco biotechnology company developing novel drugs from microbiome science. While at Second Genome, Peter and his team advanced a lead program into clinical trials, closed over $65 million in Series A and Series B venture financing, and negotiated strategic partnerships with value in excess of $80 million.
Earlier in his career, Peter led all commercial operations at Ingenuity Systems, a systems biology company acquired by Qiagen for $105 million. Peter began his career in life sciences as a strategy consultant in the New York office of The Wilkerson Group. He received a BS in Economics from the Wharton School at the University of Pennsylvania.